This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.
An informed consent document signed and dated by the subject.
Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.
Clinically relevant evidence or history of illness or disease.
Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening and infection with SARS-CoV-2 at the Day -1 visit
Pregnant or nursing females.
History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
Parallel
EDP-978
DrugOral administration
Placebo
DrugPlacebo to match EDP-978, oral administration
Safety measured by adverse events
Safety measured by adverse events
Cmax of EDP-978
AUC of EDP-978
Cmax of EDP-978
AUC of EDP-978
Click on the lead sponsor to view all of their trials.
